Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nepidermin

Next Previous
X
Search
Drug Profile

Nepidermin

Alternative Names: DWP-401; Easyef; Recombinant human epidermal growth factor - Daewoong; rhEGF - Daewoong

Latest Information Update: 28 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Growth factors; Skin disorder therapies
  • Mechanism of Action Epidermal growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diabetic foot ulcer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Alopecia; Diabetic foot ulcer; Wounds
  • Phase III Stomatitis
  • No development reported Dry eyes

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for phase-I development in Dry-eyes(In volunteers) in South Korea (Ophthalmic, Drops)
  • 08 Apr 2020 Daewoong completes a clinical trial in acute wound in Indonesia (NCT05335720)
  • 13 Nov 2019 Daewood Bio completes a phase I trial in Dry eyes (In volunteers) in South Korea (Ophthalmic) (NCT05219461)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top